Where can I buy Militizumab? How do patients obtain this medicine?

Mirikizumab is a monoclonal antibody used to treat immune diseases such as moderate to severe ulcerative colitis. Since militizumab has not yet been approved for marketing in China, patients cannot purchase the drug directly in China and therefore need to obtain it through other channels.

The original drug of militizumab has been approved in some countries and regions and is sold on the drug market in these places. For example, in Europe and the United States, militizumab is already approved for the treatment of immune-related diseases such as ulcerative colitis. In these countries, patients can obtain medications with a doctor's prescription through a medical facility or pharmacy. Taking the European version of the original drug as an example, a box of 300mg/15ml sells for about more than 10,000 yuan. However, patients should note that it is very important to obtain medicines through formal channels to ensure the quality and safety of medicines.

Because militizumab is a drug that needs to be used in a professional medical setting, patients usually need to obtain it through hospitals and professional medical facilities. In some countries where Militizumab has been approved for marketing, patients can purchase the drug through hospital pharmacies or designated drug suppliers. Patients need to be evaluated by a doctor to see if they are suitable for using this drug, and purchase and use it under the guidance of the doctor according to the treatment plan.

If the patient's country has not yet approved militizumab for marketing, or the drug has not yet been included in the medical insurance system, the patient may consider obtaining the drug through cross-border drug purchase. Such services are usually provided through overseas drug purchasing platforms or professional drug importers, and patients can purchase militizumab abroad through these platforms. It should be noted that there are certain risks in this method, and patients should ensure that the drugs they purchase come from regular sources and ensure the authenticity of the drugs.

For some drugs that are not yet on the market, participating in clinical trials is one way patients may choose. Militizumab currently has multiple ongoing clinical trials around the world, and patients can talk to their doctors about the opportunity to obtain the drug through clinical trials. In addition, drug regulatory agencies in some countries and regions provide special clinical approval channels, allowing patients to obtain treatment based on doctors' recommendations even if the drug has not yet been officially launched.

Reference materials:https://omvoh.lilly.com/